The 5 Most Interesting Analyst Questions From RadNet's Q1 Earnings Call

RadNet’s first quarter results were defined by the interplay of weather-related disruptions and ongoing investment in advanced imaging technologies. Management attributed the softer start to the quarter to severe winter storms in the Northeast and wildfires in Southern California, which negatively impacted patient volumes and revenue, particularly in January and February. CEO Howard Berger emphasized that, despite these challenges, “the business recovered to levels in March, April and the early part of May that are consistent with the strong growth trends.” The company also noted continued momentum in advanced imaging and AI-powered diagnostic tools as offsetting factors.

Is now the time to buy RDNT? Find out in our full research report (it’s free).

While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.

Our Top 5 Analyst Questions RadNet’s Q1 Earnings Call

• Brian Tanquilut (Jefferies) asked about the sustainability of advanced imaging growth and drivers behind it. CEO Howard Berger cited investments in newer equipment and AI tools as enablers of capacity and demand, with PET/CT and cardiac imaging highlighted as major growth areas.

• Grayson McAlister (Truist Securities) inquired about technologist hiring trends and the financial impact of labor costs. Berger noted some improvement in hiring and emphasized that TechLive is expected to reduce staffing costs over time.

• Andrew Mok (Barclays) questioned why higher revenue did not translate to improved earnings. CFO Mark Stolper explained that seasonality, front-loaded expenses, and one-time compensation costs weighed on margins in the quarter.

• Larry Solow (CJS Securities) probed the timeline for Medicare reimbursement for AI screenings and implementation of new technology. Berger stated that commercial payors may move faster than Medicare and that full operational rollout of workflow technology is targeted by year-end, with margin benefits expected in 2026.

• Brandon Carney (Riley) asked about pricing dynamics in PET/CT tracers and their impact on profitability. Stolper clarified that most reimbursement for new tracers is pass-through and that declining prices should not materially affect margins.

Catalysts in Upcoming Quarters

The StockStory team will be monitoring (1) the pace of TechLive and DeepHealth technology adoption across RadNet’s network, (2) successful integration and commercialization efforts following the iCAD acquisition, and (3) progress in securing payer reimbursement for AI-assisted screenings. We will also track new joint venture agreements and the ramp-up of recently opened centers as key signposts of execution.

RadNet currently trades at $57.38, up from $55.80 just before the earnings. At this price, is it a buy or sell? Find out in our full research report (it’s free).

High-Quality Stocks for All Market Conditions

The market surged in 2024 and reached record highs after Donald Trump’s presidential victory in November, but questions about new economic policies are adding much uncertainty for 2025.

While the crowd speculates what might happen next, we’re homing in on the companies that can succeed regardless of the political or macroeconomic environment. Put yourself in the driver’s seat and build a durable portfolio by checking out our Top 5 Growth Stocks for this month. This is a curated list of our High Quality stocks that have generated a market-beating return of 183% over the last five years (as of March 31st 2025).

Stocks that made our list in 2020 include now familiar names such as Nvidia (+1,545% between March 2020 and March 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today.